Cue Biopharma (CUE) Stock Statistics & Valuation Metrics

Cue Biopharma has a market cap or net worth of $174.20M. The enterprise value is $191.53.

Cue Biopharma has 7,264,414 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cue Biopharma’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -86.59%.

The current PE Ratio of Cue Biopharma is ―. Cue Biopharma’s PEG ratio is 0.02.

In the last 12 months, Cue Biopharma had revenue of 27.47M and earned -26.60M in profits. Earnings per share was -8.40.

In the last 12 months, operating cash flow was -50.05M and capital expenditures -121.00K, giving a free cash flow of -50.17M billion.

Cue Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Cue Biopharma upcoming earnings date is Nov 12, 2026, TBA (Confirmed).

Cue Biopharma as a current ratio of 2.74, with Debt / Equity ratio of 133.20%

In the past 12 months, Cue Biopharma has paid 500.00K in taxes.

Cue Biopharma EV to EBITDA ratio is -0.27, with an EV/FCF ratio of -0.27.

Cue Biopharma has $17.39M in cash and marketable securities with $3.08M in debt, giving a net cash position of $14.31M billion.

Gross margin is 99.69%, with operating margin of -96.56%, and net profit margin of -96.85%.

The average price target for Cue Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―